Date: 2017-12-12
Type of
information: Recruitment of the first patient
phase: 2
Announcement: recruitment of the first patient
Company: Tapimmune (USA - FL)
Product: TPIV200
Action
mechanism:
- immunotherapy product/therapeutic vaccine. TPIV 200 is a multi-epitope peptide vaccine that targets Folate Receptor Alpha (FRa), a molecule that is overexpressed on the surface of the vast majority of TNBC cancer cells and is associated with cancer recurrence. As an off-the-shelf vaccine consisting of several carefully chosen FRa peptides, TPIV200 is uniquely able to stimulate both T “helper” cells and T “killer” cells to target tumor cells and is expected to cover greater than 85% of human genotypes worldwide.
Disease: prevention of cancer recurrence in women with triple-negative breast cancer (TNBC) who have completed first-line surgery and radiotherapy/chemotherapy
Therapeutic
area: Cancer - Oncology
Country: USA
Trial
details:
Latest
news:
- • On December 12, 2017, TapImmune announced that the first patient has been enrolled in a Phase 2 randomized, multi-center, double-blinded, placebo-controlled clinical trial of TapImmune’s novel therapeutic vaccine candidate TPIV200. The 280-patient trial, sponsored by Mayo Clinic, received $13.3 million in grant funding from the U.S. Department of Defense (DoD) to evaluate the prevention of cancer recurrence in women with triple-negative breast cancer (TNBC) who have completed first-line surgery and radiotherapy/chemotherapy.
- Keith L. Knutson. Ph.D., Professor of Immunology in the Department of Immunology, and Edith A. Perez, M.D., Professor of Medicine in the Division of Hematology and Oncology, both at Mayo Clinic’s Florida campus in Jacksonville, Florida, are the recipients of the U.S. Department of Defense grant and are leading the Phase 2 trial.
Is
general: Yes
